knowledge -WSS

knowledge

author：fashion 2025-10-02 23:30:12 - browse：98

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Many immigrants are left out of maternal health programs

leisure time

WSS

Sutter Health’s antitrust win overturned by appeals court

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Europe is fastest

Structure Therapeutics oral GLP

Teacher posts viral 'school supply rant' with advice for parents

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

As demand for Covid shots wanes, Moderna seeks its next success

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

BioMarin wins approval for gene therapy to treat hemophilia A

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Drug repurposing or repositioning? The language matters

Fight over Supreme Court dialysis ruling puts kidney patients at risk

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Doctors in states that ban abortion can still help patients

Cancer drug shortages should be causing more outrage

Illumina board agrees to spin off Grail, as divestment plans proceed

focus

Doctors in states that ban abortion can still help patients

Congress needs to close a vaccine

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

FDA approves Moderna’s RSV vaccine, its second licensed product

Teacher posts viral 'school supply rant' with advice for parents

Data don't support strong claims for Covid

hotspot

leisure time

Wikipedia

entertainment